Whilst many disease areas have seen novel therapies reach the market, therapeutic innovation in kidney disease has been lacking, and patients are in dire need of new options. Currently, when patients progress to end-stage renal disease, they are faced with two options: dialysis or kidney transplant. Both of these treatment routes are burdensome for patients and expensive for healthcare systems and society, with costs concentrated in late-stage disease where intervention comes too late.

Recent economic modelling from the Lancet suggests the annual direct costs of diagnosed CKD and renal replacement therapies in in 31 select countries and regions will exceed US $400 bn by 2027.

At Purespring, we are re-imagining gene therapy delivery for kidney diseases, pioneering podocyte-targeted, genetic therapies that act through gene replacement or augmentation to minimise systemic effects and deliver durable efficacy to transform the trajectory of disease for renal patients.